Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds

Collins, 2003, MRC/BHF Heart Protection study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7 LaRosa, 1999, Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials, JAMA, 282, 2340, 10.1001/jama.282.24.2340 Haffner, 2003, Epidemic obesity and the metabolic syndrome, Circulation, 108, 1541, 10.1161/01.CIR.0000088845.17586.EC Bloomfield, 2001, Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention trial (VA-HIT), Circulation, 103, 2828, 10.1161/01.CIR.103.23.2828 Frick, 1987, Helsinki Heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia, N Engl J Med, 317, 1237, 10.1056/NEJM198711123172001 Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604 Sakai, 2001, Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol, Arterioscler Thromb Vasc Biol, 21, 1783, 10.1161/hq1001.096624 Shepherd, 1979, Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism, J Clin Invest, 63, 858, 10.1172/JCI109385 Brown, 1995, Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease, Ann NY Acad Sci, 748, 407, 10.1111/j.1749-6632.1994.tb17337.x Brown, 2001, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, N Engl J Med, 345, 1583, 10.1056/NEJMoa011090 Follmann, 1992, Variance imputation for overviews of clinical trials with continuous response, J Clin Epidemiol, 45, 769, 10.1016/0895-4356(92)90054-Q DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 Dumont, 2001, Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men, Int J Obes Relat Metab Disord, 25, 1136, 10.1038/sj.ijo.0801665 Frick, 1997, Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol, Circulation, 96, 2137, 10.1161/01.CIR.96.7.2137 Kahri, 1993, Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus, Atherosclerosis, 102, 79, 10.1016/0021-9150(93)90086-A Knipscheer, 1994, Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis, J Intern Med, 236, 377, 10.1111/j.1365-2796.1994.tb00813.x Lahdenpera, 1993, Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes, Diabetes Care, 16, 584, 10.2337/diacare.16.4.584 Leaf, 1989, The hypolipidemic effects of gemfibrozil in type V hyperlipidemia, JAMA, 262, 3154, 10.1001/jama.1989.03430220077034 Miller, 1993, Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study, Am J Med, 94, 7, 10.1016/0002-9343(93)90113-4 O'Neal, 1998, Gemfibrozil treatment increases low-density lipoprotein particle size in type 2 diabetes mellitus but does not alter in vitro oxidizability, Diabetes Med, 15, 870, 10.1002/(SICI)1096-9136(199810)15:10<870::AID-DIA680>3.0.CO;2-8 Rabkin, 1988, Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia, Atherosclerosis, 73, 233, 10.1016/0021-9150(88)90046-9 Roglans, 2002, Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver, Clin Pharmacol Ther, 72, 692, 10.1067/mcp.2002.128605 Vanhanen, 1995, Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination, Atherosclerosis, 115, 135, 10.1016/0021-9150(94)05474-W Wiklund, 1993, Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia, Am J Med, 94, 13, 10.1016/0002-9343(93)90114-5 Yoshida, 1998, Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study, Atherosclerosis, 139, 179, 10.1016/S0021-9150(98)00062-8 Yuan, 1994, Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy, Atherosclerosis, 110, 1, 10.1016/0021-9150(94)90062-0 Zambon, 1999, Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation, Metabolism, 48, 47, 10.1016/S0026-0495(99)90009-4 Brown, 1986, Effects of fenofibrate on plasma lipids, Arteriosclerosis, 6, 670, 10.1161/01.ATV.6.6.670 Feher, 1999, Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate, Diabetes Metab Res Rev, 15, 395, 10.1002/(SICI)1520-7560(199911/12)15:6<395::AID-DMRR65>3.0.CO;2-N Genest, 2000, Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state, J Cardiovasc Pharmacol, 35, 164, 10.1097/00005344-200001000-00022 Goldberg, 1989, Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter U.S, study. Clin Ther, 11, 69 Hodgson, 2002, Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes, Eur J Clin Nutr, 56, 1137, 10.1038/sj.ejcn.1601464 Knopp, 1987, Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E, Am J Med, 83, 75, 10.1016/0002-9343(87)90875-8 Krempf, 2000, Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia, Diabetes Metab, 26, 184 Levin, 2000, A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate, Clin Nephrol, 53, 140 Mellies, 1987, Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia, Atherosclerosis, 63, 57, 10.1016/0021-9150(87)90082-7 Playford, 2003, Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes, Atherosclerosis, 168, 169, 10.1016/S0021-9150(02)00417-3 Sasaki, 2002, Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study, Clin Ther, 24, 1614, 10.1016/S0149-2918(02)80064-9 Vakkilainen, 2003, Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention study (DAIS), Circulation, 107, 1733, 10.1161/01.CIR.0000057982.50167.6E Watts, 2003, Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome, Diabetes, 52, 803, 10.2337/diabetes.52.3.803 Cavallero, 2003, Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control, Atherosclerosis, 166, 151, 10.1016/S0021-9150(02)00321-0 de Man, 2000, Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia: effects of bezafibrate therapy, Arterioscler Thromb Vasc Biol, 20, 2434, 10.1161/01.ATV.20.11.2434 Alberti, 1990, Effect of bezafibrate on metabolic profiles in non-insulin-dependent diabetes mellitus, J Cardiovasc Pharmacol, 16, S21, 10.1097/00005344-199006169-00005 Bradford, 1992, Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia, Atherosclerosis, 92, 31, 10.1016/0021-9150(92)90007-4 Eagles, 1996, A comparison of the effects of fluvastatin and bezafibrate on exercise metabolism: a placebo-controlled study in healthy normolipidaemic subjects, Br J Clin Pharmacol, 41, 381, 10.1046/j.1365-2125.1996.03415.x Elkeles, 1998, Cardiovascular outcomes in type 2 diabetes, Diabetes Care, 21, 641, 10.2337/diacare.21.4.641 2000, Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study, Circulation, 102, 21, 10.1161/01.CIR.102.1.21 Meade, 2002, Bezafibrate in men with lower extremity arterial disease: randomised controlled trial, BMJ, 325, 1139, 10.1136/bmj.325.7373.1139 Mordasini, 1981, Reduced LDL and increased HDL apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate, Atherosclerosis, 40, 153, 10.1016/0021-9150(81)90033-2 Niort, 1993, Bezafibrate affects lipid, Horm Metab Res, 25, 372, 10.1055/s-2007-1002122 Pazzucconi, 1992, Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia, Eur J Clin Pharmacol, 43, 219, 10.1007/BF02333013 Ruotolo, 1998, J Am Coll Cardiol, 32, 1648, 10.1016/S0735-1097(98)00442-2 Winocour, 1992, The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia, Atherosclerosis, 93, 83, 10.1016/0021-9150(92)90202-R 1972, The coronary drug project, JAMA, 221, 918, 10.1001/jama.1972.03200210062030 Cohn, 1975, Effect of clofibrate on progression of coronary disease: a prospective angiographic study in man, Am Heart J, 89, 591, 10.1016/0002-8703(75)90504-9 Crouse, 1981, Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia, Metabolism, 30, 123, 10.1016/0026-0495(81)90160-8 Daubresse, 1979, Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents, Br J Clin Pharmacol, 7, 599, 10.1111/j.1365-2125.1979.tb04649.x Schneider, 1979, Effect of polyenyl phosphatidyl choline on clofibrate-induced increase in LDL cholesterol, Eur J Clin Pharmacol, 15, 15, 10.1007/BF00563553 Seplowitz, 1981, Comparison of the effects of colestipol hydrochloride and clofibrate on plasma lipids and lipoproteins in the treatment of hypercholesterolemia, Atherosclerosis, 39, 35, 10.1016/0021-9150(81)90086-1 Vecchio, 1982, Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia, Arch Intern Med, 142, 721, 10.1001/archinte.1982.00340170077016 Zelis, 1972, Type IV hyperlipoproteinemia, JAMA, 222, 326, 10.1001/jama.1972.03210030048013 Illingworth, 1982, Ciprofibrate in the therapy of type II hypercholesterolemia, Atherosclerosis, 44, 211, 10.1016/0021-9150(82)90115-0 Kontopoulos, 1996, Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease, Coron Artery Dis, 7, 843, 10.1097/00019501-199611000-00009 Brown, 1997, Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease, Am J Cardiol, 80, 111, 10.1016/S0002-9149(97)00303-2 Garg, 1990, Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus, JAMA, 264, 723, 10.1001/jama.1990.03450060069031 King, 1994, Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia, Am J Med, 97, 323, 10.1016/0002-9343(94)90298-4 Knopp, 1998, Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia, Metabolism, 47, 1097, 10.1016/S0026-0495(98)90284-0 Elam, 2000, Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial, JAMA, 284, 1263, 10.1001/jama.284.10.1263 Mostaza, 1997, Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia, Am J Cardiol, 79, 1298, 10.1016/S0002-9149(97)00109-4 Vega, 1994, Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia, Arch Intern Med, 154, 73, 10.1001/archinte.1994.00420010101012 Wink, 2002, Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy, Am Heart J, 143, 514, 10.1067/mhj.2002.120158 O'Kane, 1992, A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia, Br J Clin Pharmacol, 33, 451, 10.1111/j.1365-2125.1992.tb04067.x O'Keefe, 1995, Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia, Am J Cardiol, 76, 480, 10.1016/S0002-9149(99)80134-9 Ball, 1986, Acipimox in the treatment of patients with hyperlipidaemia: a double blind trial, Eur J Clin Pharmacol, 31, 201, 10.1007/BF00606659 Crepaldi, 1988, Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia, Atherosclerosis, 70, 115, 10.1016/0021-9150(88)90105-0 Davoren, 1998, Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus, Metabolism, 47, 250, 10.1016/S0026-0495(98)90252-9 Dean, 1992, The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia, Diabetes Med, 9, 611, 10.1111/j.1464-5491.1992.tb01855.x Fulcher, 1992, A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus, Diabetes Med, 9, 908, 10.1111/j.1464-5491.1992.tb01730.x Koev, 1993, Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment, Diabetes Care, 16, 1285, 10.2337/diacare.16.9.1285 Otto, 1998, Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia, Br J Clin Pharmacol, 46, 473, 10.1046/j.1365-2125.1998.00816.x Taskinen, 1988, Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia, Atherosclerosis, 69, 249, 10.1016/0021-9150(88)90021-4 Vaag, 1992, Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus, Acta Endocrinol (Copenh), 127, 344, 10.1530/acta.0.1270344 Grundy, 2002, Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial, Arch Intern Med, 162, 1568, 10.1001/archinte.162.14.1568 Kuvin, 2002, A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression, Am Heart J, 144, 165, 10.1067/mhj.2002.123145 Davignon, 1994, Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia, Am J Cardiol, 73, 339, 10.1016/0002-9149(94)90005-1 Morgan, 2003, Effects of extended-release niacin on lipoprotein subclass distribution, Am J Cardiol, 91, 1432, 10.1016/S0002-9149(03)00394-1 Goldberg, 1998, Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study, Am J Cardiol, 82, 35U, 10.1016/S0002-9149(98)00952-7 Aronov, 1996, Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia, Arch Fam Med, 5, 567, 10.1001/archfami.5.10.567 Keenan, 1991, Niacin revisited, Arch Intern Med, 151, 1424, 10.1001/archinte.1991.00400070172024 Vacek, 1995, Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia, Am J Cardiol, 76, 182, 10.1016/S0002-9149(99)80056-3 Lavie, 1992, Marked benefit with sustained-release niacin therapy in patients with “isolated” very low levels of high-density lipoprotein cholesterol and coronary artery disease, Am J Cardiol, 69, 1083, 10.1016/0002-9149(92)90868-Y Keenan, 1992, Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin, J Am Geriatr Soc, 40, 12, 10.1111/j.1532-5415.1992.tb01822.x Newman, 1996, Carcinogenicity of lipid-lowering drugs, JAMA, 275, 55, 10.1001/jama.1996.03530250059028 Robins, 2001, Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial, JAMA, 285, 1585, 10.1001/jama.285.12.1585 Prueksaritanont, 2002, Effects of fibrates on metabolism of statins in human hepatocytes, Drug Metab Dispos, 30, 1280, 10.1124/dmd.30.11.1280 Carlson, 1988, Reduction of mortality in the Stockholm ischemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid, Acta Med Scand, 223, 405, 10.1111/j.0954-6820.1988.tb15891.x Sacks, 2000, Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project, Circulation, 102, 1893, 10.1161/01.CIR.102.16.1893 Nissen, 2003, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial, JAMA, 290, 2292, 10.1001/jama.290.17.2292 Nissen, 2004, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial, JAMA, 291, 1071, 10.1001/jama.291.9.1071 Brousseau, 2004, Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol, N Engl J Med, 350, 1505, 10.1056/NEJMoa031766